225 related articles for article (PubMed ID: 30810334)
1. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
Vallard A; Magné N; Guy JB; Espenel S; Rancoule C; Diao P; Deutsch E; Rivera S; Chargari C
Br J Radiol; 2019 May; 92(1097):20170657. PubMed ID: 30810334
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
[TBL] [Abstract][Full Text] [Related]
3. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
[TBL] [Abstract][Full Text] [Related]
4. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
5. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
6. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Valachis A; Nearchou AD; Lind P
Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
[TBL] [Abstract][Full Text] [Related]
7. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.
Bernstein-Molho R; Laitman Y; Galper S; Jacobson G; Boursi B; Gal-Yam EN; Kaufman B; Friedman E; Kaidar-Person O
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1332-1340. PubMed ID: 33259931
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
9. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
Davey MG; Davey CM; Ryan ÉJ; Lowery AJ; Kerin MJ
Breast; 2021 Apr; 56():26-34. PubMed ID: 33582622
[TBL] [Abstract][Full Text] [Related]
10. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
Pierce LJ; Strawderman M; Narod SA; Oliviotto I; Eisen A; Dawson L; Gaffney D; Solin LJ; Nixon A; Garber J; Berg C; Isaacs C; Heimann R; Olopade OI; Haffty B; Weber BL
J Clin Oncol; 2000 Oct; 18(19):3360-9. PubMed ID: 11013276
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.
Hallam S; Govindarajulu S; Huckett B; Bahl A
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):527-35. PubMed ID: 26113392
[TBL] [Abstract][Full Text] [Related]
12. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
[TBL] [Abstract][Full Text] [Related]
13. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
Liu X; Wang Y; Cao K; Yao L; Hu L; Sun J; Zhang J; Xu Y; Xie Y
Breast Cancer Res Treat; 2023 May; 199(1):25-33. PubMed ID: 36930346
[TBL] [Abstract][Full Text] [Related]
14. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
[TBL] [Abstract][Full Text] [Related]
15. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
16. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
Wang C; Lin Y; Zhu H; Zhou Y; Mao F; Huang X; Zhou X; Cao X; Sun Q
Breast Cancer; 2022 Mar; 29(2):314-323. PubMed ID: 34766244
[TBL] [Abstract][Full Text] [Related]
17. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
[TBL] [Abstract][Full Text] [Related]
19. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]